SACT Administration and Patient Care - Postgraduate

Credit bearing module

Find a course


Key facts

Course code


Start dates

September 2023 / January 2024

Application deadline

1 September (for a September start)

1 January (for a January start)

Course length

Part time: Two semesters

Academic level


Academic credits


More details

Delivery dates:

Semester 1 & 2 (online) 
Intro session - 25/9/2023, 5pm-6pm
Day 1 - 27/9/2023, 9.30am-4pm
Day 2 - 25/10/2023, 9.30am-4pm
Drop-in session - 03/11/2023, 5pm-6pm (optional)
Day 3 - 15/11/2023, 9.30am-4pm
Day 4 - 13/12/2023, 9.30am-4pm
Close-up - 18/12/2023, 5pm-6pm (optional)

This course is not available to students classed as International for fees purposes.


This is a single practice module designed for registered nurses who are required to administer systemic anti-cancer therapy (SACT), or in the case of uro-oncology nurses, intravesical anti-cancer treatment. This module provides you with the opportunity to develop an in-depth understanding of systemic anti-cancer treatments (SACTs). You will develop the required knowledge and skills to be able to autonomously, safely and competently administer systemic or intravesical anti-cancer therapy.

This module has been designed by professionals experienced in delivering a range of cancer care education, as well as being involved in current practice in the administration of systemic or intravesical anti-cancer therapy. The content of this course aligns with National Chemotherapy Measures (NICE 2018) and the UKONS SACT Competency Passport (2019).


student taking notes

How to apply

Entry requirements


  • Nursing Midwifery Council Registration.
  • Evidence of support of the manager from practice area.
  • Signed Practice Assessor Form to evidence nominated practice assessor who can supervise and assess practice learning.
  • Be employed or have access to a health care setting that will enable achievement of the learning outcomes.
  • Competence in administration of non-cytotoxic intravenous medication including bolus infusions for students gaining competence in administration of intravenous anti-cancer treatments.
  • Competence in cannulation for students gaining competence in administration of intravenous anti-cancer treatments to adult patients.
  • Competence in urethral catheterisation (male and female) for students gaining competence in administration of intravesical anti-cancer treatments.

Terms and Conditions of Enrolment

When you accept our offer, you agree to the Terms and Conditions of Enrolment. You should therefore read those conditions before accepting the offer.

Application process

Apply through our Moodle Portal.

You will need to register for the portal prior to proceeding with an application.

Tuition fees

Please see the fees note
2024 / 25
CPD Home (UK) part time
£1,000 per module if taken as a standalone module or £1,155 per module if taken as part of an award bearing course

Questions about fees?

Contact Student Finance on:

Tuition fees

2024 / 25
CPD Home (UK) part time
£1,000 per module if taken as a standalone module or £1,155 per module if taken as part of an award bearing course

Questions about fees?

Contact Student Finance on:

+44 (0)1865 534400

Fees quoted are for the first year only. If you are studying a course that lasts longer than one year your fees will increase each year.

How and when to pay

Tuition fee instalments for the semester are due by the Monday of week 1 of each semester. Students are not liable for full fees for that semester if they leave before week 4. If the leaving date is after week 4, full fees for the semester are payable.

  • For information on payment methods please see our Make a Payment page.
  • For information about refunds please visit our Refund policy page

Financial support and scholarships

For general sources of financial support, see our Fees and funding pages.

Additional costs

Please be aware that some courses will involve some additional costs that are not covered by your fees. Specific additional costs for this course are detailed below.

Learning and assessment

The teaching, learning and assessment strategy of the module reflects its student centred, patient-centred and practice-focused approach. The module has an appropriate division between structured learning activities and private study. All of the learning methods to be used will engage the student in both academic and practice learning.

You will have to undertake a period of supervised practice in the administration of systemic or intravesical anti-cancer therapy to gain competence in administering systemic or intravesical anti-cancer therapy against learning outcomes. This will be in your own place of work or a practice setting in which systemic or intravesical anti-cancer therapy is given. Arranged by your manager, under the supervision of an agreed practice assessor nominated by your manager who meets current national standards, such as the Cancer Measures Chemotherapy Assessor standards.

student doing course work

Learning and teaching

The module explores the biological mechanisms targeted by SACTs, the mechanism of action of SACT, treatment efficacy and side effects of individual drugs. The module focuses on the use of stratified healthcare, based on pharmacogenomics data, and the management of treatment-related toxicities in patients receiving SACTS, illustrated by patient case studies.

You will be encouraged to synthesise clinical findings with concepts from current evidence-based SACT practices, and critically analyse your decision making in relation to patient care.

The teaching sessions will incorporate the following, delivered over 4 learning units, where you will be supported to develop the skills and knowledge required for achieving the learning outcomes.


Assessment methods used on this course

The assessment is in 2 parts – you must pass both components to pass the module:

  1. you must correctly complete all exercises in the UKONS Passport/Workbook
  2. a 3000-word critical reflection that includes:
    • a description of the case study and diagnostic biomarkers/cytogenetics (if applicable)
    • a scientific rationale for the use of the SACT prescribed
    • a critical appraisal of evidence base of the efficacy of the SACT, making reference to stratified patient populations, primary endpoints, quality of life outcomes/side effects/toxicity profiles
    • in-depth knowledge of side effect management.

Programme changes:
On rare occasions we may need to make changes to our course programmes after they have been published on the website. For more information, please visit our changes to programmes page.